Drug Detail

Information about Olverembatinib

Generic Name	Olverembatinib
IND	HQP1351
Brand Name (US)
Manufacturer	Ascentage Pharma
Drug Type	Tyrosine Kinase Inhibitor
Delivery	Oral
Approval Status	Phase 1
Indications
Overall Strategy	KIT Protein Based
Strategy	Block KIT
Drug Category	SDH-directed

HQP1351 is a novel kinase inhibitor developed by Ascentage Pharma. It is an oral third-generation BCR-ABL inhibitor targeting a broad spectrum of BCR-ABL mutants, including those with the T315I mutation, to treat drug-resistant CML patients. A Phase I clinical trial for patients with TKI-resistant CML has been completed and the pivotal Phase II clinical trials are ongoing in China. In addition, a Phase Ib trial in patients with GIST and a Phase Ib trial are also ongoing in China and in the U.S., respectively.